Tag: EQT

REYKJAVIK, Islande et LONDRES, 20 juill. 2025 (GLOBE NEWSWIRE) -- Aztiq a vendu la majorité de sa participation dans Adalvo à EQT, une société d’investissement internationale détenant un portefeuille d’entreprises et d’actifs en Europe, en Asie-Pacifique et en Amérique. Fondée par Aztiq en 2018 et recensant plus de 280 employés et 170 partenariats commerciaux dans plus de 140 pays, Adalvo figure parmi les principales entreprises pharmaceutiques interentreprises (B2B) en Europe.

PITTSBURGH, July 16, 2025 /PRNewswire/ -- EQT Corporation (NYSE: EQT) today announced that its Board of Directors declared a quarterly cash dividend on its common...

EQT Healthcare Growth to acquire Europa Biosite, a distributor of over ten million high-quality life science reagents to academic and biopharma researchers across Europe...

PITTSBURGH, July 2, 2025 /PRNewswire/ -- EQT Corporation (NYSE: EQT) plans to issue its second quarter financial and operating results news release after market...

Four-building, Class A industrial portfolio totals 2.04 million square feet in Manteca, California  Located near major highways and an intermodal rail terminal, the properties...

Four-building, Class A industrial portfolio totals 2.04 million square feet in Manteca, California  Located near major highways and an intermodal rail terminal, the properties...

EQT to sell Pioneer, a leading Japanese provider of in-car sound and multimedia products and solutions for global OEMs and the consumer aftermarket, for...

Company Marks Milestone as World's First Large-Scale Traditional Energy Producer to Achieve Net Zero Scope 1 & 2 Greenhouse Gas Emissions PITTSBURGH, June 24, 2025...

THIS IS INFORMATION THAT EQT AB (PUBL) IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SUBMITTED FOR...

Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support...

Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical TrialsBiotech veteran David Weber has been appointed CEO...